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S UMMA R Y
OB J E C T I V E : To assess the clinical outcomes of patients
prescribed the World Health Organization (WHO)
Category II retreatment regimen for tuberculosis (TB).
DE S I GN : A systematic review of the literature was
performed by searching Medscape, Embase and Scopus
databases for cohort studies and clinical trials reporting
outcomes in adult patients on the Category II retreat-
ment regimen.
R E SU LT S : The proportion of patients successfully com-
pleting the retreatment regimen varied from 27% to
92% in the 39 studies included in this review. In only 2/
39 (5%) studies was the treatment success rate . 85%.
There are very few data concerning outcomes in patients
categorised as ‘other’, and outcomes in this subgroup are
variable. Of the five studies reporting disaggregated
outcomes in human immunodeficiency virus (HIV)
positive people, four demonstrated worse outcomes
than in HIV-negative people on the retreatment regimen.
Only four studies reported disaggregated outcomes in
patients with isoniazid (INH) resistance, and treatment
success rates varied from 11% to 78%.
CONC LU S I ON : Clinical outcomes on the Category II
retreatment regimen are poor across various popula-
tions. Improvements in management should consider the
holistic treatment of comorbidity and comprehensive
approaches to drug resistance in patients with recurrent
TB, including a standardised approach for the manage-
ment of INH resistance in patients who develop
recurrent TB in settings without reliable access to
comprehensive drug susceptibility testing.
K E Y WORD S : relapse; recurrent; streptomycin; cure;
isoniazid
OF THE 6.6 MILLION PEOPLE worldwide reported
to have tuberculosis (TB) in 2016, approximately
300000 had previously received treatment.1 Until
recently, in settings with low or medium prevalence of
multidrug-resistant TB (MDR-TB, defined as TB
resistant to at least isoniazid [INH, H] and rifampicin
[RMP, R]) and no routine access to drug susceptibility
testing (DST), the World Health Organization (WHO)
recommended that previously treated patients with TB
be prescribed an empirical regimen comprising 2
months of RMP, INH, pyrazinamide (Z), ethambutol
(E) and streptomycin (SM, S), followed by 1 month of
RHZE and 5 months of RHE.2 This ‘Category II’
regimen was devised based on expert opinion;
however, there have been no clinical trial data on
which to assess its efficacy. WHO guidelines published
in 2017 recommended that the Category II regimen
should no longer be prescribed and that DST be
conducted to inform the choice of treatment regimen.3
However, given the lack of data on which to base
decisions regarding retreatment, this recommendation
is presented only as a good practice statement.
In 1991, the World Health Assembly set a target to
cure 85% of patients who receive treatment for
sputum smear-positive TB.4 In recent years, giant
steps have been taken to meet these targets, with 83%
of new cases now successfully cured.1 However, rates
of successful treatment are consistently lower in
patients prescribed the retreatment regimen. A
meta-analysis of studies evaluating outcomes in
patients who were retreated for TB identified only
six cohort studies reporting outcomes for the
Category II regimen.5 These studies demonstrated
treatment failure rates of between 0% and 27% in
patients infected with a fully susceptible strain of TB;
however, in patients with INH monoresistance (INH-
R) and either mixed or unknown resistance patterns,
failure rates were even higher, at respectively 18–44%
and 9–45%. This meta-analysis only included pa-
tients with microbiologically confirmed TB, and
therefore excluded a large number of patients who
had sputum smear-negative or extra-pulmonary TB
(EPTB), and in whom outcomes are likely to be even
worse.6
Patients receiving Category II retreatment are
classified into four categories: sputum smear-positive
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relapse, treatment after failure, treatment after
default (now known as loss to follow-up), and ‘other,’
which consists largely of patients who have smear-
negative or extra-pulmonary recurrence. The under-
lying disease processes, and therefore clinical out-
comes, may vary significantly between these
categories. For example, those with true relapse
almost certainly have TB and are therefore likely to
respond to retreatment, whereas those classified as
‘other’ may be presenting with symptoms caused by
an alternative disease (e.g., cancer or bronchiectasis),
for which anti-tuberculosis treatment will be ineffec-
tive. In addition, although drug resistance is more
prevalent in people with recurrent TB than people
presenting with a first episode of TB, only a minority
are infected with a resistant strain in most settings.
Moreover, although recent WHO guidelines advocate
phasing out the Category II regimen in favour of
treatment based on DST results, a large number of
patients with recurrent disease will not have micro-
biologically confirmed disease; decisions will there-
fore have to be made without information about
resistance patterns on which to base treatment
regimens.
We performed a protocol-driven systematic review
of the literature7 to examine clinical outcomes on a
TB retreatment regimen in both microbiologically
confirmed and unconfirmed cases, including those
registered as ‘other.’ We examined outcomes in
different groups of patients to consider possible
factors that may be associated with the poor
outcomes seen in patients with recurrent TB.
METHODOLOGY
Information sources and search strategy
Medscape, Embase and Scopus databases were
searched using the following search terms: ‘Tubercu-
losis’ ‘retreat*’, (Category II) and (Category 2).
Searches were limited to manuscripts published in
English after 1991 and concerning human subjects. A
manual search of the journal Public Health Action
was performed, as it was a relatively new journal and
likely to publish relevant manuscripts. Reference lists
of identified studies were examined for further
relevant publications.
Eligibility
Prospective or retrospective cohort studies or clinical
trials reporting outcomes in adult patients prescribed
the Category II TB retreatment regimen were
included. The review included studies published after
1991, as this was when the standardised retreatment
regimen was introduced. Only studies published in
English were included. Studies reporting on patients
receiving regimens for TB other than the standard
WHO Category II regimen, studies that did not use
standard WHO definitions for reporting TB out-
comes (cured, completed, failed, died, lost to follow-
up, not evaluated8), and reports including only
patients withMDR-TB receiving retreatment regimen
were excluded.
Study selection and data collection process
After removal of duplicates, study titles, then
abstracts, and finally full texts of manuscripts were
reviewed. Two reviewers (DBC and JM) assessed
manuscripts independently at each stage and, if
discrepancies arose, consensus was reached by
discussion between the two reviewers and a third
reviewer (SBS).
Data were extracted and entered directly into a
standardised spreadsheet and included details of the
study design, setting, population characteristics,
treatment regimens, reporting definitions, number
of study participants and baseline smear status.
Outcomes for the total study population and sub-
groups, including TB category, HIV status and INH
susceptibility pattern, were recorded. An evaluation
of the generalisability of each study was made based
on inclusion criteria and data source.
Summary measures and synthesis of results
The specific endpoint of interest was the proportion
of patients in whom an outcome of ‘treatment
success’ was recorded. Treatment success was a
composite of ‘cured’ and ‘completed’. ‘Cured’ was
defined as being smear-negative at the end of
treatment having started smear-positive. ‘Completed’
was defined as finishing a course of treatment, but not
meeting the criteria for cure.9 The proportion of
patients with a successful treatment outcome was
then calculated for each study. Data were analysed
using STATA v12 (StataCorp, College Station, TX,
USA) and I2 estimates derived for the assessment of
heterogeneity between studies.
RESULTS
A total of 1038 publications were identified after
removing duplicates (Figure 1). After examination of
72 full-text articles, 39 studies were included in the
final analysis (Table 1).10–48 The majority of the
studies included in the review (33/39) were retro-
spective cohorts based on analyses of routinely
collected data in local or national TB registers. The
majority of the studies were conducted in Asia
(predominantly India) or Africa. See Appendix Table
A* for study details.
* The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2018/
00000022/00000010/art00006
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Overall outcomes on tuberculosis retreatment
regimen
The proportion of patients successfully completing a
retreatment regimen ranged from 27% to 92%.
There was significant heterogeneity between studies
(I2¼ 0.95), which precluded calculation of a pooled
estimate. Only 2/39 (5%) studies met the target of
85%, successful treatment. The treatment success
rate was ,75% in 29 (74%) studies, and ,50% in
four studies.
Outcomes on tuberculosis retreatment regimen by
category
The successful completion rate in patients with TB
relapse was 770% in all studies, and confidence
intervals (CIs) around these estimates tended to be
small (Figure 2A). Outcomes in patients registered as
having returned to treatment after default or having
failed treatment varied more widely, at 41–74% and
34–85%, respectively (Figures 2B and 2C). Very few
Figure 1 Study selection. MDR-TB ¼ multidrug-resistant
tuberculosis.
Figure 2 Treatment outcomes according to TB retreatment category: A) retreatment after relapse; B) retreatment after default (loss
to follow-up); C) treatment after failure; and D) other. TB¼ tuberculosis.
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Table 1 Studies describing outcomes on TB retreatment regimen
Author, year Country Study design n
Success rate
% Population under study
Studies conducted in Asia
Abeygunawardena, 201410 Sri Lanka RC 160 82 All patients registered at a district chest clinic
Bam, 200711 Nepal RC 118 92 Smear-positive patients being treated for TB at
refugee camps
Becx-Bleumink, 199912 Indonesia PC 239 87 Smear-positive patients prospectively enrolled in a
pilot of ambulatory treatment
Burugina Nagaraja, 201113 India RC 202 34 Patients from TB registration centres in seven districts
who had failed treatment
Chandrasekaran, 200714 India RC 699 43 Smear-positive patients from all TB registration
centres in one district
Chughtai, 201315 Pakistan RC 12656 78 All patients registered for treatment of pulmonary TB
across the country
Deepa, 201316 India RC 1077 67 Smear-positive patients registered at all TB centres in
one state
Halim, 200617 Indonesia RC 107 70 All patients registered at a central hospital
Kumar, 201018 India RC 133 64 All patients registered at centres in one district
Kumar, 201419 India PC 38 55 All HIV-positive patients treated for failure, relapse or
default at a research centre
Mehra, 200820 India RC 517 70 Patients treated for failure and relapse TB at a single
urban chest clinic
Mukherjee, 200921 India RC 234 68 Smear-positive patients registered at a regional TB
unit
Mukhopadhyay, 201122 India RC 140 69 All patients registered two TB units in one district
(one urban, one rural)
Pardeshi, 200723 India RC 507 66 Smear-positive patients registered in one district
Sarpal, 201424 India RC 545 81 All patients registered in one district
Sisodia, 200625 India RC 2215 74 Smear-positive patients registered in four districts
Srinath, 201126 India RC 5365 76 All patients registered in one state
Vasudevan, 201427 India RC 133 67 All patients registered in one district
Win, 201228 Myanmar RC 3643 73 All patients registered across the country
Studies conducted in Africa
Akpabio, 201129 South Africa RC 388 27 All patients with pulmonary TB registered at a
regional TB hospital
Bohler, 200530 Sudan RC 62 68 Smear-positive patients registered at five TB
management units in IDP camps
Bachmann, 201031 South Africa CT 1 385 62 All patients prospectively enrolled into the PALSA trial
Berhe, 201232 Ethiopia RC 22 64 Smear-positive patients registered in 10 rural and five
urban districts
Dooley, 201133 Morocco RC 291 73 Smear or culture-positive patients registered at nine
urban TB clinics
Gninafon, 200434 Benin RC 236 78 Smear-positive patients registered at a large urban
referral hospital
Ige, 201135 Nigeria RC 127 74 All patients starting treatment at a university hospital
Jones-Lopez, 201136 Uganda PC 288 77 Smear-positive patients treated as in-patients at a TB
referral centre
Munoz-Sellart, 201037 Ethiopia RC 338 66 All patients registered at seven health centres
Nakanwagi-Mukwaya, 201338 Uganda RC 105 46 All relapse, failure and default patients registered at
three regional referral hospitals
Ottmani, 200639 Morocco RC 14635 71 All bacteriologically confirmed cases registered across
the country
Salaniponi, 200340 Malawi RC 741 65 Smear-positive patients registered at non-private
health facilities
Takarinda, 201241 Zimbabwe RC 225 72 All patients registered in one district
Tweya, 201142 Malawi RC 411 67 All patients registered across the country
Wahome, 201343 Kenya RC 46 61 All health care workers working at a referral hospital
Studies conducted in other regions
Espinal, 200044 Multicentre PC 876 57 DR-TB survey in Dominican Republic, Hong Kong
SAR, China, Italy, Russia, Korea and Peru
Furin, 201245 Georgia RC 6633 58 All patients registered for anti-tuberculosis treatment
across the country
McGreevy, 201246 Haiti RC 153 78 All patients registered at a TB-HIV referral centre
Ponce, 201247 Peru CT 111 71 Smear-positive patients registered in three districts
Sevim, 200248 Turkey RC 47 83 Relapse and default patients registered at one referral
clinic
TB¼ tuberculosis; RC¼ retrospective cohort; PC¼prospective cohort; HIV¼human immunodeficiency virus; CT¼clinical trial; PALSA¼Practical Approach to Lung
Health in sub-Saharan Africa; IDP¼ internally displaced persons; DR-TB¼ drug-resistant TB; SAR¼ special administrative region.
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studies specifically reported outcomes in patients
registered as ‘other’. The rate of successful treatment
in this group varied from 61% to 84% (Figure 2D).
Outcomes on a tuberculosis retreatment regimen by
isoniazid resistance
Disaggregated data for outcomes among patients
with confirmed INH resistance were reported in four
studies, involving only 217 patients (Table 2). Three
of the four studies were conducted in India, and in
these the prevalence of INH-R ranged from 12% to
28%. The largest of the studies aimed to compare
outcomes in patients with and without INH-R, and
found that 44% of those with INH-R had poor
treatment outcomes, compared with 31% of those
infected with a susceptible strain (adjusted relative
risk [aRR] 1.46, 95%CI 1.19–1.78).16
Outcomes on tuberculosis retreatment regimen by
human immunodeficiency virus status
Only five studies compared outcomes in HIV-positive
and HIV-negative patients (Table 3). Two were
conducted in African countries with generalised
HIVepidemics (Uganda and Zimbabwe), one in Haiti
(HIV prevalence , 2%), one in Indonesia (HIV
prevalence 0.5%), and one in India (HIV prevalence
, 0.5%). In 4/5 studies, outcomes were worse in
HIV-infected patients. In the one study that reported
higher success rates in HIV-positive people, the
number of HIV-negative patients was very small.
Jonez-Lopez et al. reported an adjusted odds ratio
(OR) of 2.16 (95%CI 1.01–4.61) for unsuccessful
outcome in HIV-positive patients in Uganda, with
factors associated with death being CD4 count , 50
cells/ml, no antiretroviral therapy (ART) and Karnof-
sky score , 70%.36 In a study by McGreevy et al.,
follow-up data demonstrated that only 46% of HIV-
positive patients remained alive, in ART care and TB-
free after a median of 36 months of follow-up.46
DISCUSSION
This review demonstrated that, in keeping with
previous reports, rates of successful treatment using
the WHO Category II regimen for TB retreatment
were consistently lower than the target of 85%. We
presented disaggregated data available for TB retreat-
ment subgroups; although data were limited, out-
comes may have been worse in HIV-infected adults,
those with INH-R, and patients with smear-negative
TB and EPTB registered as ‘other’.
It is often assumed that low success rates in patients
on the Category II regimen are due to the increased
prevalence of drug resistance in this group, which is
associated with higher rates of treatment failure and
relapse.49,50 With better access to molecular DST
through Xpertw MTB/RIF (Cepheid, Sunnyvale, CA,
USA),51 it is increasingly possible to identify patients
with RMP resistance indicative of MDR-TB, who can
be managed on second-line regimens. However,
concerns remain regarding patients who have cul-
ture-negative TB for whom it is not possible to
determine resistance patterns, and in settings where
comprehensive DST is unavailable, so RMP resis-
tance (but not INH-R) is diagnosed using Xpert.
INH-R affects 12% of previously treated cases
worldwide;52 however, prevalence has been estimated
to vary widely between regions.53 INH is a crucial
component of TB treatment regimens—it has greater
early bactericidal activity than other drugs and has
the greatest impact on clinical outcomes.54,55 As the
purpose of an extended empirical drug regimen for
patients with recurrent TB is to treat presumed drug
resistance, the regimen should primarily be targeted
at treating INH-R. Unfortunately, few studies have
reported outcomes in patients with INH-R who
received the Category II regimen. Evidence for the
treatment of INH-R is lacking; however, the few data
available indicate that the addition of SM to the
intensive phase is associated with improved out-
comes.5,56
The overall pattern of outcomes in this study
suggested a lower rate of successful retreatment in
patients who had failed initial anti-tuberculosis
treatment than in patients who had relapsed follow-
ing treatment. The high rate of treatment success in
‘relapsed’ patients may be largely explained by the
fact that patients in this group have confirmed TB
Table 2 TB retreatment outcomes by INH resistance status
Study
Treatment success in INH resistance
n/N (%) (95%CI)
Burugina-Nagaraga, 201113 5/46 (11) (4–24)
Deepa, 201316 80/144 (56) (47–64)
Kumar, 201419 3/4 (75) (19–99)
Salaniponi, 200340 18/23 (78) (56–93)
TB¼ tuberculosis; INH¼ isoniazid.
Table 3 TB retreatment outcomes by HIV status
Study
Treatment success in HIV-positive patients
n/N (%) (95%CI)
Treatment success in HIV-negative patients
n/N (%) (95%CI)
Ige, 201135 27/42 (64) (49–79) 67/83 (81) (73–89)
Jonez-Lopez, 201136 103/140 (74) (67–81) 118/148 (80) (74–86)
McGreevy, 201246 41/56 (73) (61–85) 79/97 (81) (73–89)
Srinath, 201126 38/55 (69) (57–81) 97/111 (87) (81–93)
Takarinda, 201241 101/135 (75) (68–82) 15/21 (71) (52–90)
TB¼ tuberculosis; HIV¼ human immunodeficiency virus; CI¼ confidence interval.
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disease. Furthermore, some ‘relapses’ may in fact be
reinfections with susceptible strains. In well-run TB
control programmes, failure on first-line treatment is
rare and more commonly associated with drug-
resistant TB than other categories of retreatment.57
This may well account for lower success rates in this
group, although drug resistance patterns were not
always reported. Our findings support current
treatment recommendations that, in settings where
rapid DST is not routinely available, patients who
have failed treatment should be started on an
empirical MDR-TB regimen, unless it is known that
drug resistance rates are low in that population.3,58
Particularly in settings where the prevalence of
drug-resistant TB is low, several other factors may
contribute to poor outcomes among patients with
recurrent TB. First, some patients may not have TB at
all, in which case the misdiagnosis will result in
treating for TB and not the true underlying disease.
While several studies have examined alternative
causes of smear-negative TB in patients presenting
with a first episode of TB, data exploring this issue in
patients being retreated are scarce.59,60 Data from
this review support such a theory, as patients
classified as ‘other’ seemed to do worse than those
who relapsed with a confirmed TB diagnosis. This is
of particular concern as they make up the largest
proportion of patients prescribed a retreatment
regimen.
Second, other comorbid conditions which both
predispose to TB and are associated with worse
outcomes may be prevalent in this group.61 The
phenomenon of post-tuberculous lung disease is well
recognised.62–64 By definition, as all patients receiv-
ing the Category II regimen have had a previous
episode of TB, the burden of chronic lung disease in
this group is likely to be high. Those with chronic
lung damage may be misclassified as having recurrent
pulmonary TB or may have worse outcomes even in
the event of true recurrence.
HIV-TB co-infected patients are known to have
worse outcomes than HIV-negative patients after an
initial episode of TB.65 Our review suggests that this
is also the case in retreatment, but the underlying
mechanism for this cannot be assumed to be the same.
As people established on ART live for many years, but
remain at an increased risk of TB, they are more likely
to have multiple TB episodes.66 An increased
possibility of ART failure in patients who have been
on long-term ART is likely to complicate the clinical
picture of recurrent TB even further.
Third, due to prolonged treatment duration and the
addition of SM to the retreatment regimen, drug
toxicities may be common and result in discontinu-
ation or interruption of treatment.67,68 Finally, this
longer and more demanding regimen may be associ-
ated with poor adherence and increased rates of
default from treatment.
Our study had some limitations. There remains a
lack of information regarding the efficacy of the
Category II regimen in different subpopulations,
particularly among patients who have smear-negative
or extra-pulmonary disease. Studies are also lacking
from key regions such as South America and Eastern
Europe. It should be noted that data evaluating the
correlation between drug resistance patterns and
outcomes on this regimen are insufficient.
Some obvious issues must be addressed if clinical
outcomes on retreatment are to be improved. The
need to identify drug resistance promptly to prevent
inappropriate use of retreatment regimens is now
widely recognised, and further expansion of molec-
ular DST testing in this group is required to facilitate
this strategy. However, the inability to diagnose INH-
R in most clinical settings and the lack of evidence
about how to treat INH-R are key priorities to
address. If randomised trials can establish the best
treatment for INH-R, there may be an argument to
use regimens against INH-R empirically for all
patients with recurrent TB in settings where DST is
not available. Lastly, it may be that compared with
patients with a first TB episode, there is a higher
burden of other comorbidities, such as HIV and
chronic lung disease, in this population, which also
needs to be addressed if outcomes are to improve.
People who receive the Category II retreatment
regimen are a complex and heterogeneous group of
patients. The regimen has no clinical trial evidence
base and outcomes are poor across different regions
and groups of patients. There are multiple possible
explanations for these poor outcomes. The challenge
of improving the management of recurrent TB will
need to look beyond simply identifying those patients
who have MDR-TB, and begin to incorporate
appropriate approaches to the management of non-
MDR-TB drug resistance, as well as address the
spectrum of comorbidities from which patients on TB
retreatment suffer.
Acknowledgements
DBC and JM received Wellcome Trust (London, UK) training
fellowship grants. SBS was the supervisor for DBC and JM.
Conflicts of interest: none declared.
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
References
1 World Health Organization. Global tuberculosis report, 2017.
WHO/HTM/TB/2017.23. Geneva, Switzerland: WHO, 2017.
2 World Health Organization. Treatment of tuberculosis:
guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva,
Switzerland: WHO, 2010.
3 World Health Organization. Guidelines for treatment of drug-
susceptible tuberculosis and patient care. WHO/HTM/TB/
2017.05. Geneva, Switzerland: WHO, 2017.
1132 The International Journal of Tuberculosis and Lung Disease
4 World Health Organization. Tuberculosis control programme.
44th World Health Assembly General, 6–16 May 1991.
WHA44.8. Geneva, Switzerland: WHO, 1991.
5 Menzies D, Benedetti A, Paydar A, et al. Standardized
treatment of active tuberculosis in patients with previous
treatment and/or with mono-resistance to isoniazid: a
systematic review and meta-analysis. PLOS Med 2009; 6:
e1000150.
6 Tweya H, Kanyerere H, Ben-Smith A, et al. Re-treatment
tuberculosis cases categorised as ’other’: are they properly
managed? PLOS ONE 2011; 6: e28034.
7 Moher D, Liberati A, Tetzlaff J, Altman D G, Group P.
Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. J Clin Epidemiol 2009; 62:
1006–1012.
8 World Health Organization. Definitions and reporting
framework for tuberculosis: 2013 revision. Geneva,
Switzerland: WHO, 2014.
9 World Health Organization. Definitions and reporting
framework for tuberculosis: 2013 revision. Geneva,
Switzerland: WHO, 2013.
10 Abeygunawardena S C, Sharath B N, Van den Bergh R, Naik B,
Pallewatte N, Masaima M N N. Management of previously
treated tuberculosis patients in Kalutara district, Sri Lanka:
how are we faring? Public Health Action 2014; 4: 105–109.
11 Bam T S, Enarson D A, Hinderaker S G, Chapman R S. High
success rate of TB treatment among Bhutanese refugees in
Nepal. Int J Tuberc Lung Dis 2007; 11: 54–58.
12 Becx-BleuminkM, Djamaluddin S, Loprang F, de Soldenhoff R,
Wibowo H, Aryono M. High cure rates in smear-positive
tuberculosis patients using ambulatory treatment with once-
weekly supervision during the intensive phase in Sulawesi,
Republic of Indonesia. Int J Tuberc Lung Dis 1999; 3: 1066–
1072.
13 Burugina Nagaraja S, Satyanarayana S, Chadha S S, et al. How
do patients who fail first-line TB treatment but who are not
placed on anMDR-TB regimen fare in South India? PLOSONE
2011; 6: e25698.
14 Chandrasekaran V, Gopi P G, Santha T, Subramani R,
Narayanan P R. Status of re-registered patients for
tuberculosis treatment under DOTS programme. Indian J
Tuberc 2007; 54: 12–16.
15 Chughtai A A, MacIntyre C R, Wang Y A, Gao Z, Khan W.
Treatment outcomes of various types of tuberculosis in
Pakistan, 2006 and 2007. East Mediterr Health J 2013; 19:
535–541.
16 Deepa D, Achanta S, Jaju J, et al. The impact of isoniazid
resistance on the treatment outcomes of smear-positive re-
treatment tuberculosis patients in the state of Andhra Pradesh,
India. PLOS ONE 2013; 8: e76189.
17 Halim H, Rasyid A, Ahmad Z. Evaluation of four-years
hospital implementation of DOTS strategy (1998–2002). Acta
Med Indones 2006; 38: 130–134.
18 Kumar A, Pandit V, Pattanshetty S, Shetty R, Roy S, Krish S. A
study on treatment outcome of registered tuberculosis cases
under RNTCP in Udupi Taluk, Karnataka. J Commun Dis
2010; 42: 45–51.
19 Kumar R, Menon PA, Ponnuraja C, et al. HIV-infected patients
retreated for tuberculosis with intermittent Category II
regimen—treatment outcome at 24-month follow-up. Indian J
Tuberc 2014; 61: 43–50.
20 Mehra R K, Dhingra V K, Nish A, Vashist R P. Study of relapse
and failure cases of CAT I retreated with CAT II under
RNTCP—an eleven-year follow up. Indian J Tuberc 2008; 55:
188–191.
21 Mukherjee A, Sarkar A, Saha I, Biswas B, Bhattacharyya P S.
Outcomes of different subgroups of smear-positive retreatment
patients under RNTCP in rural West Bengal, India. Rural
Remote Health 2009; 9: 926.
22 Mukhopadhyay S, Sarkar A P. Comparative analysis of RNTCP
indicators in a rural and an urban tuberculosis unit of Burdwan
district in West Bengal. Indian J Community Med 2011; 36:
146–149.
23 Pardeshi G S, Deshmukh D. A comparison of treatment
outcome in re-treatment versus new smear positive cases of
tuberculosis under RNTCP. Indian J Public Health 2007; 51:
237–239.
24 Sarpal S S, Goel N K, Kumar D, Janmeja A K. Treatment
outcome among the retreatment tuberculosis patients under
RNTCP in Chandigarh, India. J Clin Diagn Res 2014; 8: 53–56.
25 Sisodia R S, Wares D F, Sahu S, Chauhan L S, Zignol M. Source
of retreatment cases under the Revised National TB Control
Programme in Rajasthan, India, 2003. Int J Tuberc Lung Dis
2006; 10 : 1373–1379.
26 Srinath S, Sharath B, Santosha K, et al. Tuberculosis
’retreatment others’: Profile and treatment outcomes in the
state of Andhra Pradesh, India. Int J Tuberc Lung Dis 2011; 15:
105–109.
27 Vasudevan K, Jayakumar N, Gnanasekaran D. Smear
conversion, Treatment outcomes and the time of default in
registered tuberculosis patients on RNTCP DOTS in
Puducherry, South India. J Clin Diagn Res 2014; 8: JC05–JC08.
28 Win AN, EdgintonME, Hinderaker S G,MinnNN, Linn A K.
Tuberculosis treatment outcomes among retreatment patients
registered by private practitioners in Myanmar. Public Health
Action 2012; 2: 79–81.
29 Akpabio U S, De Villiers P J T. A description of patients with
recurrence of pulmonary tuberculosis in a tuberculosis hospital,
Ermelo. Afr J Prim Health Care Fam Med 2011; 3: 261.
30 Bohler M, Mustafaa S A, Morkve O. Tuberculosis treatment
outcome and health services: A comparison of displaced and
settled population groups in Khartoum, Sudan. Int J Tuberc
Lung Dis 2005; 9: 32–36.
31 Bachmann M O, Fairall L R, Lombard C, et al. Effect on
tuberculosis outcomes of educational outreach to south African
clinics during two randomised trials. Int J Tuberc Lung Dis
2010; 14: 311–317.
32 Berhe G, Enquselassie F, Aseffa A. Treatment outcome of
smear-positive pulmonary tuberculosis patients in Tigray
Region, Northern Ethiopia. BMC Public Health 2012; 12: 537.
33 Dooley K E, Lahlou O, Ghali I, et al. Risk factors for
tuberculosis treatment failure, default, or relapse and outcomes
of retreatment in Morocco. BMC Public Health 2011; 11: 140.
34 Gninafon M, Tawo L, Kassa F, et al. Outcome of tuberculosis
retreatment in routine conditions in Cotonou, Benin. Int J
Tuberc Lung Dis 2004; 8: 1242–1247.
35 Ige OM, AkindeleMO. Five year review of treatment outcome
of directly observed therapy (DOT) for re-treatment pulmonary
tuberculosis patients in UCH, Ibadan, Nigeria. Afr J Med Med
Sci 2011; 40: 15–21.
36 Jones-Lopez E C, Ayakaka I, Levin J, et al. Effectiveness of the
standard WHO recommended retreatment regimen (Category
II) for tuberculosis in Kampala, Uganda: a prospective cohort
study. PLOS Med 2011; 8: e1000427.
37 Munoz-Sellart M, Cuevas L E, Tumato M, Merid Y, Yassin M
A. Factors associated with poor tuberculosis treatment outcome
in the Southern Region of Ethiopia. Int J Tuberc Lung Dis 2010;
14: 973–979.
38 Nakanwagi-Mukwaya A, Reid A J, Fujiwara P I, et al.
Characteristics and treatment outcomes of tuberculosis
retreatment cases in three regional hospitals, Uganda. Public
Health Action 2013; 3: 149–155.
39 Ottmani S E, Zignol M, Bencheikh N, Laaˆsri L, Chaouki N,
Mahjour J. Results of cohort analysis by category of
tuberculosis retreatment cases in Morocco from 1996 to
2003. Int J Tuberc Lung Dis 2006; 10: 1367–1372.
40 Salaniponi F M, Nyirenda T E, Kemp J R, Squire S B, Godfrey-
Faussett P, Harries A D. Characteristics, management and
Outcomes of the WHO retreatment regimen 1133
outcome of patients with recurrent tuberculosis under routine
programme conditions in Malawi. Int J Tuberc Lung Dis 2003;
7: 948–952.
41 Takarinda K C, Harries A D, Srinath S, Mutasa-Apollo T,
Sandy C, Mugurungi O. Treatment outcomes of adult patients
with recurrent tuberculosis in relation to HIV status in
Zimbabwe: a retrospective record review. BMC Public Health
2012; 12: 124.
42 Tweya H, Kanyerere H, Ben-Smith A, et al. Re-treatment
tuberculosis cases categorised as ’other’: are they properly
managed? PLOS ONE 2011; 6: e28034.
43 Wahome E, Makori L, Gikera M, et al. Tuberculosis treatment
outcomes among hospital workers at a public teaching and
national referral hospital in Kenya. Public Health Action 2013;
3: 323–327.
44 Espinal M A, Kim S J, Suarez P G, et al. Standard short-course
chemotherapy for drug-resistant tuberculosis: treatment
outcomes in 6 countries. JAMA 2000; 283: 2537–2545.
45 Furin J, Gegia M, Mitnick C, et al. Eliminating the category II
retreatment regimen from national tuberculosis programme
guidelines: the Georgian experience. Bull World Health Organ
2012; 90: 63–66.
46 McGreevy J, Jean Juste M A, Severe P, et al. Outcomes of HIV-
infected patients treated for recurrent tuberculosis with the
standard retreatment regimen. Int J Tuberc Lung Dis 2012; 16:
841–845.
47 Ponce M, Ugarte-Gil C, Zamudio C, Krapp F, Gotuzzo E, Seas
C. Additional evidence to support the phasing-out of treatment
category II regimen for pulmonary tuberculosis in Peru. Trans R
Soc Trop Med Hyg 2012; 106: 508–510.
48 Sevim T, Atac¸ G, Gu¨ngo¨r G, et al. Treatment outcome of relapse
and defaulter pulmonary tuberculosis patients. Int J Tuberc
Lung Dis 2002; 6: 320–325.
49 Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al.
Retreatment tuberculosis cases. Factors associated with drug
resistance and adverse outcomes. Chest 1997; 111: 1162–1167.
50 Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug
resistance and tuberculosis treatment outcomes: systematic
review and meta-analysis. Ann Intern Med 2008; 149: 123–
134.
51 Lawn S D, Mwaba P, Bates M, et al. Advances in tuberculosis
diagnostics: the Xpert MTB/RIF assay and future prospects for
a point-of-care test. Lancet Infect Dis 2013; 13: 349–361.
52 World Health Organization. Anti-tuberculosis drug resistance
in the world: fourth global report. WHO/HTM/TB/2008.394.
Geneva, Switzerland: WHO, 2008.
53 Jenkins H E, Zignol M, Cohen T. Quantifying the burden and
trends of isoniazid-resistant tuberculosis, 1994–2009. PLOS
ONE 2011; 6: e22927.
54 Donald P R, Diacon A H. The early bactericidal activity of anti-
tuberculosis drugs: a literature review. Tuberculosis (Edinb)
2008; 88 (Suppl 1): S75–S83.
55 Huyen M N, Cobelens F G, Buu T N, et al. Epidemiology of
isoniazid resistance mutations and their effect on tuberculosis
treatment outcomes. Antimicrob Agents Chemother 2013; 57:
3620–3627.
56 Gegia M,Winters N, Benedetti A, van Soolingen D,Menzies D.
Treatment of isoniazid-resistant tuberculosis with first-line
drugs: a systematic review and meta-analysis. Lancet Infect Dis
2017; 17: 223–234.
57 Quy H T, Lan N T, Borgdorff M W, et al. Drug resistance
among failure and relapse cases of tuberculosis: is the standard
re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7:
631–636.
58 Nahid P, Dorman S E, Alipanah N, et al. Official American
Thoracic Society/Centers for Disease Control and Prevention/
Infectious Diseases Society of America clinical practice
guidelines: treatment of drug-susceptible tuberculosis. Clin
Infect Dis 2016; 63: e147–e195.
59 Hargreaves N J, Kadzakumanja O, Phiri S, et al. What causes
smear-negative pulmonary tuberculosis in Malawi, an area of
high HIV seroprevalence? Int J Tuberc Lung Dis 2001; 5: 113–
122.
60 WorodriaW, Okot-NwangM, Yoo SD, Aisu T. Causes of lower
respiratory infection in HIV-infected Ugandan adults who are
sputum AFB smear-negative. Int J Tuberc Lung Dis 2003; 7:
117–123.
61 Metcalfe J Z, Mason P, Mungofa S, Sandy C, Hopewell P C.
Empiric tuberculosis treatment in retreatment patients in high
HIV/tuberculosis-burden settings. Lancet Infect Dis 2014; 14:
794–795.
62 Hicks A, Muthukumarasamy S, Maxwell D, Howlett D.
Chronic inactive pulmonary tuberculosis and treatment
sequelae: chest radiographic features. Int J Tuberc Lung Dis
2014; 18: 128–133.
63 Lee J J, Chong P Y, Lin C B, Hsu A H, Lee C C. High resolution
chest CT in patients with pulmonary tuberculosis: characteristic
findings before and after antituberculous therapy. Eur J Radiol
2008; 67: 100–104.
64 Ryu Y J, Lee J H, Chun E M, Chang J H, Shim S S. Clinical
outcomes and prognostic factors in patients with tuberculous
destroyed lung. Int J Tuberc Lung Dis 2011; 15: 246–250, i.
65 Aaron L, Saadoun D, Calatroni I, et al. Tuberculosis in HIV-
infected patients: a comprehensive review. Clin Microbiol
Infect 2004; 10: 388–398.
66 Gupta A, Wood R, Kaplan R, Bekker L G, Lawn S D.
Tuberculosis incidence rates during 8 years of follow-up of an
antiretroviral treatment cohort in South Africa: comparison
with rates in the community. PLOS ONE 2012; 7: e34156.
67 Forget E J, Menzies D. Adverse reactions to first-line
antituberculosis drugs. Expert Opin Drug Saf 2006; 5: 231–
249.
68 Lv X, Tang S, Xia Y, et al. Adverse reactions due to directly
observed treatment strategy therapy in Chinese tuberculosis
patients: a prospective study. PLOS ONE 2013; 8: e65037.
1134 The International Journal of Tuberculosis and Lung Disease
APPENDIX
Ta
b
le
A
C
la
ss
if
ic
at
io
n
o
f
tr
ea
tm
en
t
o
u
tc
o
m
es
fo
r
st
u
d
ie
s
in
cl
u
d
ed
in
th
is
re
vi
ew
St
u
d
y,
ye
ar
,
re
fe
re
n
ce
Su
cc
es
s
in
IN
H
-R
n
(%
)
Su
cc
es
s
ra
te
b
y
tr
ea
tm
en
t
ca
te
g
o
ry
To
ta
l
ca
se
s
N
C
u
re
d
n
C
o
m
p
le
te
d
n
Fa
ile
d
n
D
ie
d
n
M
o
rt
al
it
y
%
D
ef
au
lt
n
U
k/
TO n
To
ta
l
su
cc
es
s
n
Su
cc
es
s
ra
te %
R
el
ap
se
n
(%
)
Fa
ilu
re
n
(%
)
TA
D
n
(%
)
O
th
er
n
(%
)
A
b
ey
g
u
n
aw
ar
d
en
a,
2
0
1
4
1
0
1
6
0
1
2
6
5
1
0
6
1
1
0
1
3
1
8
2
A
kp
ab
io
,
2
0
1
1
2
9
3
8
8
1
9
8
6
9
5
1
1
3
4
9
1
7
4
1
0
5
2
7
B
o
h
le
r,
2
0
0
5
3
0
6
2
3
5
7
0
1
2
1
8
1
4
2
6
8
B
ac
h
m
an
n
,
2
0
1
0
3
1
1
3
8
5
8
6
2
6
2
B
am
,
2
0
0
7
1
1
1
0
4
/1
0
8
(9
6
)
3
/8
(3
8
)
2
/2
(1
0
0
)
1
1
8
1
0
9
0
3
3
0
0
1
0
9
9
2
B
ec
x-
B
le
u
m
in
k,
1
9
9
9
1
2
2
3
9
1
8
1
2
6
1
4
6
1
0
4
2
0
7
8
7
B
er
h
e,
2
0
1
2
3
2
2
2
1
4
6
4
B
u
ru
g
in
a
N
ag
ar
aj
a,
2
0
1
1
1
3
5
/4
6
(1
1
)
6
8
/2
0
2
(3
4
)
2
0
2
8
4
3
6
1
8
1
3
1
6
8
3
4
C
h
an
d
ra
se
ka
ra
n
,
2
0
0
7
1
4
6
9
9
6
0
4
7
7
2
8
1
9
3
0
2
4
3
C
h
u
g
h
ta
i,
2
0
1
3
1
5
5
7
2
6
/6
8
3
9
(8
4
)
9
4
0
/1
2
9
6
(7
3
)
3
1
9
2
/4
5
2
1
(7
1
)
1
2
6
5
6
9
8
5
8
7
8
D
ee
p
a,
2
0
1
3
1
6
8
0
/1
4
4
(5
6
)
1
0
7
7
7
1
0
1
6
8
8
9
5
9
1
4
0
1
8
7
2
6
6
7
D
o
o
le
y,
2
0
1
1
3
3
1
7
3
/2
3
4
(7
4
)
1
0
/2
1
(4
8
)
1
5
/3
7
(4
1
)
2
7
2
1
7
2
2
6
1
1
7
3
7
3
0
1
9
8
7
3
Es
p
in
al
,
2
0
0
0
4
4
8
7
6
4
5
3
4
4
1
2
4
5
1
6
1
1
2
9
2
4
9
7
5
7
Fu
ri
n
,
2
0
1
2
4
5
6
6
3
3
1
0
3
7
3
6
6
6
6
1
9
6
8
1
3
8
5
8
5
8
G
n
in
af
o
n
,
2
0
0
4
3
4
9
0
/1
1
3
(8
0
)
7
1
/8
4
(8
5
)
2
3
/3
9
(5
9
)
2
3
6
7
1
7
7
2
8
0
1
8
4
7
8
H
al
im
,
2
0
0
6
1
7
1
0
7
7
4
1
1
1
2
2
1
6
2
7
5
7
0
Ig
e,
2
0
1
1
3
5
1
2
7
8
1
1
3
2
2
1
7
4
7
9
4
7
4
Jo
n
es
-L
o
p
ez
,
2
0
1
1
3
6
2
8
8
1
8
3
8
1
3
1
0
1
0
2
2
2
7
7
K
u
m
ar
,
2
0
1
0
1
8
1
3
3
6
1
2
4
1
1
1
1
8
1
0
1
6
8
5
6
4
K
u
m
ar
,
2
0
1
4
1
9
3
/4
(7
5
)
3
8
2
1
5
5
M
cG
re
ev
y,
2
0
1
2
4
6
1
5
3
6
1
4
9
1
3
0
1
2
0
7
8
M
eh
ra
,
2
0
0
8
2
0
2
9
8
/3
9
0
(7
6
)
6
2
/1
2
7
(4
9
)
5
1
7
5
9
2
8
5
7
0
0
3
6
0
7
0
M
u
kh
er
je
e,
2
0
0
9
2
1
1
1
3
/1
5
0
(7
5
)
2
8
/5
2
(2
2
)
1
9
/3
5
(5
4
)
2
3
4
3
1
1
4
6
2
6
3
1
6
0
6
8
M
u
kh
o
p
ad
h
ya
y,
2
0
1
1
2
2
4
3
/6
1
(7
0
)
6
/1
2
(5
0
)
1
7
/3
0
(5
7
)
3
1
/3
7
(8
4
)
1
4
0
6
3
3
4
7
9
6
2
7
0
9
7
6
9
M
u
n
o
z-
Se
lla
rt
,
2
0
1
0
3
7
1
0
6
/1
4
2
(7
5
)
8
/1
6
(5
0
)
1
3
/2
0
(6
5
)
9
7
/1
6
0
6
1
)
1
9
2
1
2
7
6
6
N
ak
an
w
ag
i-
M
u
kw
ay
a,
2
0
1
3
3
8
1
0
5
0
9
9
2
4
6
4
8
4
6
O
tt
m
an
i,
2
0
0
6
3
9
8
9
3
9
/1
1
9
5
1
(7
5
)
4
3
7
/7
5
3
(5
8
)
9
8
5
/1
9
3
1
(5
1
)
1
4
6
3
5
6
7
3
6
7
3
5
1
7
7
0
1
1
5
6
1
0
3
7
6
7
1
Pa
rd
es
h
i,
2
0
0
7
2
3
1
0
0
/1
3
7
(7
3
)
4
1
/6
5
(6
3
)
1
9
6
/3
0
5
(6
4
)
5
0
7
5
2
4
0
8
7
8
3
3
7
6
6
Po
n
ce
,
2
0
1
2
4
7
1
1
1
0
7
9
7
1
Sa
la
n
ip
o
n
i,
2
0
0
3
4
0
1
8
/2
3
(7
8
)
7
4
1
1
6
2
2
2
5
1
8
2
2
5
4
4
2
6
4
8
4
6
5
Sa
rp
al
,
2
0
1
4
2
4
2
1
3
/2
6
4
(8
1
)
2
1
/3
9
(5
4
)
5
0
/7
5
(6
7
)
1
6
0
/1
6
7
(9
6
)
5
4
5
2
8
3
1
6
1
4
6
2
3
4
3
2
4
4
4
8
1
Se
vi
m
,
2
0
0
2
4
8
4
7
3
9
8
3
Si
so
d
ia
,
2
0
0
6
2
5
2
3
2
/2
8
1
(8
3
)
2
7
/3
7
(7
3
)
1
3
8
1
/1
8
9
7
(7
3
)
2
2
1
5
1
4
9
3
1
4
7
7
1
1
5
1
7
2
5
2
1
1
6
4
0
7
4
Sr
in
at
h
,
2
0
1
1
2
6
1
6
2
5
/2
0
9
4
(7
8
)
2
8
6
/4
8
2
(5
9
)
1
1
2
7
/1
5
5
2
(7
3
)
1
0
2
9
/1
2
3
7
(8
3
)
5
3
6
5
4
0
6
7
7
6
Ta
ka
ri
n
d
a,
2
0
1
2
4
1
8
2
/1
0
3
(8
0
)
2
1
/3
2
(6
8
)
6
0
/9
0
(6
7
)
2
2
5
1
1
3
6
1
4
3
2
1
6
3
7
2
Tw
ey
a,
2
0
1
1
4
2
4
1
1
2
7
4
6
7
V
as
u
d
ev
an
,
2
0
1
4
2
7
1
3
3
1
2
1
4
1
1
1
8
0
8
9
6
7
W
ah
o
m
e,
2
0
1
3
4
3
4
6
2
8
6
1
W
in
,
2
0
1
2
2
8
1
5
1
4
/1
9
8
3
(7
6
)
6
7
3
/1
0
3
3
(6
5
)
2
7
5
/3
7
3
(7
4
)
1
9
5
/2
5
4
(7
7
)
3
6
4
3
2
2
3
3
4
2
4
3
0
9
2
4
2
7
2
1
6
2
1
9
2
6
5
7
7
3
TA
D
¼
tr
ea
tm
en
t
af
te
r
d
ef
au
lt
;
IN
H
-R
¼
is
o
n
ia
zi
d
re
si
st
an
ce
;
U
k/
TO
¼
u
n
kn
o
w
n
/t
ra
n
sf
er
o
u
t.
Outcomes of the WHO retreatment regimen i
R E´ S U M E´
OB J E C T I F : Evaluer les re´sultats cliniques des patients
auxquels on a prescrit pour la tuberculose (TB) le
protocole de retraitement de l’Organisation Mondiale de
la Sante´ (OMS) de Cate´gorie II.
S CH E´MA : Une revue syste´matique de la litte´rature a e´te´
re´alise´e graˆce a` une recherche sur les bases de donne´es
Medscape, Embase et Scopus sur les e´tudes de cohorte
ou les essais cliniques rapportant les re´sultats de patients
adultes sous protocole de retraitement de Cate´gorie II.
R E´ S U LTAT S : La proportion de patients qui ont acheve´
avec succe`s le protocole de retraitement a varie´ de 27% a`
92% dans les 39 e´tudes incluses dans la revue. Le taux de
succe`s du traitement n’a e´te´ de . 85% que dans 2/39
(5%) e´tudes. Il y a peu de donne´es relatives aux re´sultats
des patients classe´s comme « autres » et les re´sultats de
ce sous-groupe sont variables. Sur les cinq e´tudes
rapportant des re´sultats de´sagre´ge´s chez les personnes
positives a` l’infection par le virus de l’immunode´ficience
humaine (VIH), quatre ont de´montre´ des re´sultats plus
me´diocres que chez les personnes VIH ne´gatives sous
protocole de retraitement. Seules quatre e´tudes ont
rapporte´ des re´sultats de´sagre´ge´s chez des patients
ayant une re´sistance a` l’isoniazide (INH) et le taux de
succe`s du traitement a varie´ de 11% a` 78%.
CONC LU S I ON : Les re´sultats cliniques du protocole de
retraitement de l’OMS de Cate´gorie II sont me´diocres
dans toutes sortes de populations. Les ame´liorations de
la prise en charge devraient porter sur un traitement
holistique des comorbidite´s et des approches inte´gre´es de
la pharmacore´sistance des patients atteints de TB
re´currente, incluant une approche standardise´e de la
prise en charge de la re´sistance a` l’INH chez les patients
qui de´veloppent une TB re´currente dans des contextes
sans acce`s fiable a` de tests exhaustifs de
pharmacosensibilite´.
R E S UM E N
O B J E T I V O: Evaluar los desenlaces clı´nicos de los
pacientes que han recibido un esquema de
retratamiento de la tuberculosis (TB) de la Categorı´a II
de la Organizacio´n Mundial de la Salud (OMS).
M E´ TODO: Se llevo´ a cabo una revisio´n sistema´tica de las
publicaciones cientı´ficas tras la bu´squeda en las bases de
datos Medscape, Embase y Scopus de estudios de
cohortes o ensayos clı´nicos que comunicaban los
desenlaces de pacientes adultos tratados con un
esquema de retratamiento de la TB de la Categorı´a II.
R E S U LTA D O S: La proporcio´n de pacientes que
completaron con e´xito el esquema de retratamiento
oscilo´ entre 27% y 92% en los 39 estudios incluidos en
la revisio´n. Solo en dos de los 39 estudios (5%) la tasa de
e´xito terape´utico fue . 85%. Se encontraron pocos
datos sobre los desenlaces de pacientes en la categorı´a
‘otros’ y en este subgrupo los resultados fueron
variables. De los cinco estudios que presentaban
desenlaces desglosados en funcio´n de la infeccio´n por
el virus de la inmunodeficiencia humana (VIH), cuatro
revelaban desenlaces ma´s desfavorables con el esquema
de retratamiento en las personas positivas que en las
personas no afectadas por el virus. Solo cuatro estudios
presentaban desenlaces desglosados en los pacientes con
resistencia a isoniazida (INH) y las tasas de e´xito
terape´utico oscilaban entre 11% y 78%.
CONC LU S I O´ N: Los desenlaces clı´nicos alcanzados con
un esquema de retratamiento de la Categorı´a II de la
OMS son deficientes en una diversidad de poblaciones.
Los progresos en la gestio´n de los casos deben tener en
cuenta el tratamiento holı´stico de las enfermedades
concomitantes y comportar estrategias integrales frente
a la farmacorresistencia en los pacientes con TB
recurrente, que incluyan un esquema normalizado de
tratamiento de la resistencia a INH en las personas con
recurrencia de la TB, en los entornos que no cuentan con
un acceso fiable a pruebas completas de sensibilidad a
los medicamentos.
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